{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:30:51Z","timestamp":1772166651208,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA048167"],"award-info":[{"award-number":["K23DA048167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA048167"],"award-info":[{"award-number":["K23DA048167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA048167"],"award-info":[{"award-number":["K23DA048167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA048167"],"award-info":[{"award-number":["K23DA048167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low. Interventions to increase MOUD access in the United States have largely focused on improving organizational capacity and addressing funding barriers, yet stigma toward MOUD may inhibit uptake even where MOUD is readily available. Non-prescribing substance use disorder (SUD) treatment professionals (e.g. counselors) likely have considerable influence on a client\u2019s choice to initiate and adhere to MOUD, but beliefs that counselors convey about MOUD in interaction with clients are understudied. The current study explores what advantages and disadvantages that counselors communicate about buprenorphine, methadone, and naltrexone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From June to December 2021, we surveyed counselors from publicly-funded SUD treatment agencies under a municipality-wide mandate to offer MOUD to all clients with OUD. Counselors were asked to describe, in a free-response format, the most important advantages and disadvantages to communicate to their clients about taking buprenorphine, methadone, and naltrexone. Counselor responses were coded for one or more advantage and disadvantage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 271 SUD counselors from 29 agencies in the Philadelphia Metropolitan Area completed the survey, generating 1,995 advantages and disadvantages across three types of MOUD. The most frequently reported advantage across all three types of MOUD was their ability to reduce cravings and illicit drug use. The most frequently reported disadvantage related to the potential for some types of MOUD to develop long-term medication dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As the availability and variety of MOUD treatment options continue to expand, it is important that SUD counselors are equipped with evidence-based recommendations for OUD care. We identified misalignments with the MOUD-prescribing evidence base and stigmatizing language toward MOUD within counselors\u2019 responses, highlighting the potential to refine training materials for MOUD and mitigate stigmatizing beliefs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-025-00537-2","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:14:33Z","timestamp":1738649673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-8565","authenticated-orcid":false,"given":"Nicholas C.","family":"Cardamone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca E.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle M.","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"3","key":"537_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid Use Disorder after Nonfatal Opioid Overdose and Association with Mortality: a Cohort Study. Ann Intern Med. 2018;169(3):137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"537_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ajad.13260","volume":"31","author":"AJ Gordon","year":"2022","unstructured":"Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, et al. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x\u2010waiver trainings. Am J Addict. 2022;31(2):152\u20138.","journal-title":"Am J Addict"},{"issue":"1","key":"537_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.12569","volume":"38","author":"CHA Andrilla","year":"2022","unstructured":"Andrilla CHA, Patterson DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2022;38(1):87\u201392.","journal-title":"J Rural Health"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2019.07.014","volume":"108","author":"K Darfler","year":"2020","unstructured":"Darfler K, Sandoval J, Pearce Antonini V, Urada D. Preliminary results of the evaluation of the California Hub and spoke Program. J Subst Abuse Treat. 2020;108:26\u201332.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR5","first-page":"263348952110058","volume":"2","author":"L Caton","year":"2021","unstructured":"Caton L, Shen H, Miele GM, Darfler K, Sandoval JR, Urada D, et al. Opening the black box: four common implementation strategies for expanding the use of medications for opioid use disorder in primary care. Implement Res Pract. 2021;2:263348952110058.","journal-title":"Implement Res Pract"},{"issue":"4","key":"537_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","volume":"11","author":"JR Brooklyn","year":"2017","unstructured":"Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of Care for Opioid Use Disorder: development, implementation, and impact. J Addict Med. 2017;11(4):286\u201392.","journal-title":"J Addict Med"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jsat.2019.07.007","volume":"108","author":"S Reif","year":"2020","unstructured":"Reif S, Brolin MF, Stewart MT, Fuchs TJ, Speaker E, Mazel SB. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders. J Subst Abuse Treat. 2020;108:33\u20139.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"109107","DOI":"10.1016\/j.drugalcdep.2021.109107","volume":"229","author":"J Cantor","year":"2021","unstructured":"Cantor J, Powell D, Kofner A, Stein BD. Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020. Drug Alcohol Depend. 2021;229:109107.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"537_CR9","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of Medication for Opioid Use Disorder among US adolescents and adults with need for Opioid Treatment, 2019. JAMA Netw Open. 2022;5(3):e223821.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"537_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68.","journal-title":"Addict Sci Clin Pract"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.rcsop.2021.100029","volume":"2","author":"A Cernasev","year":"2021","unstructured":"Cernasev A, Hohmeier KC, Frederick K, Jasmin H, Gatwood J. A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Exploratory Res Clin Social Pharm. 2021;2:100029.","journal-title":"Exploratory Res Clin Social Pharm"},{"issue":"14","key":"537_CR12","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"537_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dar.12032","volume":"32","author":"BB Chaar","year":"2013","unstructured":"Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment: factors influencing OST in pharmacy. Drug Alcohol Rev. 2013;32(4):426\u201334.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"537_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","volume":"29","author":"HK Knudsen","year":"2005","unstructured":"Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29(2):95\u2013106.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"209121","DOI":"10.1016\/j.josat.2023.209121","volume":"155","author":"E Pasman","year":"2023","unstructured":"Pasman E, O\u2019Shay S, Brown S, Madden EF, Agius E, Resko SM. Ambivalence and contingencies: a qualitative examination of peer recovery coaches\u2019 attitudes toward medications for opioid use disorder. J Subst Use Addict Treat. 2023;155:209121.","journal-title":"J Subst Use Addict Treat"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"108377","DOI":"10.1016\/j.jsat.2021.108377","volume":"129","author":"RE Stewart","year":"2021","unstructured":"Stewart RE, Shen L, Kwon N, Vigderman J, Kramer S, Mandell DS, et al. Transporting to treatment: evaluating the effectiveness of a mobile engagement unit. J Subst Abuse Treat. 2021;129:108377.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"108900","DOI":"10.1016\/j.jsat.2022.108900","volume":"144","author":"RE Stewart","year":"2023","unstructured":"Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, et al. Not in my treatment center: Leadership\u2019s perception of barriers to MOUD adoption. J Subst Abuse Treat. 2023;144:108900.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"537_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","volume":"7","author":"JJ Sanders","year":"2013","unstructured":"Sanders JJ, Roose RJ, Lubrano MC, Lucan SC. Meaning and Methadone: patient perceptions of Methadone Dose and a model to promote adherence to maintenance treatment. J Addict Med. 2013;7(5):307\u201313.","journal-title":"J Addict Med"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"100161","DOI":"10.1016\/j.ssmqr.2022.100161","volume":"2","author":"EF Madden","year":"2022","unstructured":"Madden EF, Barker KK, Guerra J, Villanueva C, Sulzer SH. Variation in intervention stigma among medications for opioid use disorder. SSM - Qualitative Res Health. 2022;2:100161.","journal-title":"SSM - Qualitative Res Health"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"209153","DOI":"10.1016\/j.josat.2023.209153","volume":"155","author":"AR Brown","year":"2023","unstructured":"Brown AR, Walters JE, Harmer B, Cates L, Jones AE. Non-prescribing clinicians\u2019 treatment orientations and attitudes toward treatments for opioid use disorder: rural differences. J Subst Use Addict Treat. 2023;155:209153.","journal-title":"J Subst Use Addict Treat"},{"issue":"4","key":"537_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jsat.2008.01.003","volume":"35","author":"EJ Santa Ana","year":"2008","unstructured":"Santa Ana EJ, Martino S, Ball SA, Nich C, Frankforter TL, Carroll KM. What is usual about treatment-as-usual? Data from two multisite effectiveness trials. J Subst Abuse Treat. 2008;35(4):369\u201379.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR22","unstructured":"Department of Behavioral Health and Intellectual disAbility Services. Provider Bulletin # 18\u2013\u200907 Community Behavioral Health Requirement for All Crisis Response Centers (CRCs) and Drug and Alcohol Licensed Providers to Establish Protocols to Assist Individuals in Accessing Evidence-Based Treatment, Including Medication-Assisted Treatment [Internet]. 2018. Available from: https:\/\/dbhids.org\/wp-content\/uploads\/2018\/06\/Provider-Bulletin-18-07-All-CRCs-and-Drug-and-Alcohol-Licensed-Providers-Will-Establish-Protocols-to-Assist-Individuals-in-Accessing-MAT-FINAL2-amended2-1.pdf"},{"issue":"2","key":"537_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"R Harris, Taylor","year":"2009","unstructured":"Harris, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"key":"537_CR24","unstructured":"Braun V, Clarke V. Thematic analysis. In: Cooper H, Camic PM, Long DL, Panter AT, Rindskopf D, Sher KJ, editors. APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological [Internet]. Washington: American Psychological Association; 2012 [cited 2023 Aug 14]. pp. 57\u201371. Available from: http:\/\/content.apa.org\/books\/13620-004"},{"issue":"1","key":"537_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33(1):159.","journal-title":"Biometrics"},{"issue":"1","key":"537_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication treatment of opioid Use Disorder. Biol Psychiatry. 2020;87(1):82\u20138.","journal-title":"Biol Psychiatry"},{"key":"537_CR27","unstructured":"Committee on Medication-Assisted Treatment for Opioid Use Disorder, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives [Internet]. Leshner AI, Mancher M, editors. Washington, D.C.: National Academies Press. 2019 [cited 2022 Oct 6]. Available from: https:\/\/www.nap.edu\/catalog\/25310"},{"key":"537_CR28","unstructured":"NIDA. How effective are medications to treat opioid use disorder? [Internet]. 2021. Available from: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/efficacy-medications-opioid-use-disorder"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","volume":"104","author":"HD Chilcoat","year":"2019","unstructured":"Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148\u201357.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"537_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/10826084.2023.2177972","volume":"58","author":"SK Rubel","year":"2023","unstructured":"Rubel SK, Eisenstat M, Wolff J, Calevski M, Mital S. Scope of, motivations for, and outcomes Associated with Buprenorphine Diversion in the United States: a scoping review. Subst Use Misuse. 2023;58(5):685\u201397.","journal-title":"Subst Use Misuse"},{"issue":"9","key":"537_CR31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the US before and after Federal Policy Changes Expanding take-home methadone doses from Opioid Treatment Programs. JAMA Psychiatry. 2022;79(9):932.","journal-title":"JAMA Psychiatry"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"108655","DOI":"10.1016\/j.jsat.2021.108655","volume":"135","author":"MTH Harris","year":"2022","unstructured":"Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. No home to take methadone to: experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Subst Abuse Treat. 2022;135:108655.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"537_CR34","doi-asserted-by":"publisher","first-page":"e231235","DOI":"10.1001\/jamahealthforum.2023.1235","volume":"4","author":"RA Harris","year":"2023","unstructured":"Harris RA, Long JA, Bao Y, Mandell DS. Racial, ethnic, and sex differences in Methadone-Involved Overdose Deaths before and after the US Federal Policy Change Expanding take-home methadone doses. JAMA Health Forum. 2023;4(6):e231235.","journal-title":"JAMA Health Forum"},{"key":"537_CR35","unstructured":"NIDA. What is the treatment need versus the diversion risk for opioid use disorder treatment? [Internet]. 2021. Available from: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/what-treatment-need-versus-diversion-risk-opioid-use-disorder-treatment"},{"key":"537_CR36","doi-asserted-by":"publisher","first-page":"108183","DOI":"10.1016\/j.jsat.2020.108183","volume":"122","author":"P Gauthier","year":"2021","unstructured":"Gauthier P, Greco P, Meyers-Ohki S, Desai A, Rotrosen J. Patients\u2019 perspectives on initiating treatment with extended-release naltrexone (XR-NTX). J Subst Abuse Treat. 2021;122:108183.","journal-title":"J Subst Abuse Treat"},{"key":"537_CR37","doi-asserted-by":"crossref","unstructured":"Stewart RE, Cardamone NC, Altman CA, Bowen J, Mandell DS. MOUD Adoption among clients of Organizations that provide MOUD or coordinate Care with External Providers. PS. 2024;appi.ps.20230522.","DOI":"10.1176\/appi.ps.20230522"},{"key":"537_CR38","first-page":"117822182211038","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, Spector A, Weeks M, Galletly C, McDonald M, Green Montaque HD. You\u2019re not supposed to be on it forever: medications to treat opioid use disorder (MOUD) related Stigma among Drug Treatment providers and people who use opioids. Substance Abuse. 2022;16:117822182211038.","journal-title":"Substance Abuse"},{"key":"537_CR39","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. Fifth Edition. American Psychiatric Association. 2013 [cited 2024 Apr 3]. Available from: https:\/\/psychiatryonline.org\/doi\/book\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"key":"537_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2014.10.001","volume":"50","author":"PD Friedmann","year":"2015","unstructured":"Friedmann PD, Wilson D, Knudsen HK, Ducharme LJ, Welsh WN, Frisman L, et al. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in Community corrections. J Subst Abuse Treat. 2015;50:50\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"537_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/appi.ps.202100675","volume":"74","author":"T Molfenter","year":"2023","unstructured":"Molfenter T, Kim H, Kim JS, Kisicki A, Knudsen HK, Horst J, et al. Enhancing Use of medications for Opioid Use Disorder through External Coaching. PS. 2023;74(3):265\u201371.","journal-title":"PS"},{"key":"537_CR42","doi-asserted-by":"crossref","unstructured":"Martin RA, Stein LaR, Rohsenow DJ, Belenko S, Hurley LE, Clarke JG et al. Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: protocol. J Subst Abuse Treat. 2021;108364\u2013108364.","DOI":"10.1016\/j.jsat.2021.108364"},{"key":"537_CR43","unstructured":"Providers Clinical Support System. -Medications for Opioid Use Disorders [Internet]. [cited 2024 Dec 10]. Providers Clinical Support System. Available from: https:\/\/pcssnow.org\/about\/"},{"key":"537_CR44","doi-asserted-by":"crossref","unstructured":"Monico LB, Fletcher JB, Ross T, Schwartz RP, Fishman MJ, Gryczynski J et al. Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder. J Subst Use Addict Treat. 2024;209334.","DOI":"10.1016\/j.josat.2024.209334"},{"key":"537_CR45","unstructured":"Beck AJ, Page C, Buche J, Rittman D, Gaiser M. Scopes of practice and reimbursement patterns of addiction counselors, community health workers, and peer recovery specialists in the behavioral health workforce [Internet]. Behavioral Health Workforce Research Center, University of Michigan School of Public Health; 2018. Available from: https:\/\/www.healthworkforceta.org\/wp-content\/uploads\/2023\/07\/BHWRC_SOPs.pdf"},{"issue":"3","key":"537_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsat.2005.11.004","volume":"30","author":"ME Kerwin","year":"2006","unstructured":"Kerwin ME, Walker-Smith K, Kirby KC. Comparative analysis of state requirements for the training of substance abuse and mental health counselors. J Subst Abuse Treat. 2006;30(3):173\u201381.","journal-title":"J Subst Abuse Treat"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00537-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:14:40Z","timestamp":1738649680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00537-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00537-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4331201\/v1","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review boards of the University of Pennsylvania and the City of Philadelphia approved the study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}